Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva/BTG Tev-Tropin

Executive Summary

Teva/Bio-Technology General Corp.'s human growth hormone Tev-Tropin will be introduced "at the earliest opportunity" following U.S. appellate court decision to vacate June 2002 preliminary injunction against U.S. marketing of the product, BTG says. The injunction was requested by Novo. The company's process patent case arose out of previous process patent litigation between BTG and Genentech, which was resolved when BTG received FDA approval to change its manufacturing process (1"The Pink Sheet" May 8, 2000, p. 22). Novo claimed BTG's manufacturing change violated Novo patents. Teva holds marketing rights to Tev-Tropin and has ultimate decision on a launch date, BTG says...

You may also be interested in...



Teva MS Success Helps Stock In Down Month: Biogen, Chiron Tumble

Teva's smooth performance in the multiple sclerosis market is shoring up the company in a difficult environment for biopharmaceutical stocks.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California

US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel